Fenwick Represents Shockwave Medical in Pending Acquisition by Johnson & Johnson

Fenwick is representing Shockwave Medical, Inc. (Nasdaq: SWAV), a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease, in its pending acquisition by Johnson & Johnson (NYSE: JNJ).

Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share, for an aggregate enterprise value of approximately $13.1 billion. The transaction is expected to close by mid-year 2024, subject to Shockwave shareholder approval, the receipt of required regulatory clearances and other customary closing conditions. More information can be obtained from Shockwave Medical’s announcement.

The Fenwick transaction team included corporate partners Doug Cogen, Bomi Lee, Ran Ben-Tzur and Jen Hitchcock and associates Chris Gorman, Jiarui Li, Liz Malmen, Christina Scully, Christian Choi, Tempestt Edward, Beth Clarke, Kaylee Johnson, Warren Pugash and Sammi Chen; technology transactions partner Stefano Quintini and associates Jennifer Yoon, Kehl Sink, Phillip Yin and Rob Ferrari; executive compensation partner Matt Cantor and associates Jonathan Stephenson and Elizabeth Fu; antitrust partner Tom Ensign and associate Elizabeth Suarez; patent litigation partner Jeff Oelke and associate Jon McMichael; healthcare regulatory partner Jennifer Yoo; and tax partner Adam Halpern and associate Einav Axler.